Chronic Disease Management — MCQs

A 73-year-old man with COPD, ischaemic heart disease, heart failure with preserved ejection fraction (HFpEF), and type 2 diabetes attends for medication review. He takes aspirin, atorvastatin, bisoprolol, furosemide, metformin, and uses tiotropium and salbutamol inhalers. He reports increasing breathlessness. Examination reveals bibasal fine crackles, mild peripheral oedema, and peak expiratory flow rate 65% of predicted (unchanged from previous). Which single medication change is most likely to improve his symptoms?

Q133

You are reviewing prescribing patterns in patients with multimorbidity in your practice. A 79-year-old woman with heart failure, atrial fibrillation, chronic kidney disease stage 3b, and previous gastrointestinal bleeding is taking bisoprolol, furosemide, apixaban 2.5mg twice daily, lansoprazole, and ferrous sulfate. Her weight is 54kg, creatinine 145 μmol/L, and age is 79 years. According to the apixaban dose reduction criteria, how many factors does she have that would justify the reduced dose she is receiving?

Q134

A 76-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and anxiety presents with worsening tremor and rigidity. His medications include co-careldopa, atorvastatin, metformin, tamsulosin, and he recently started prochlorperazine for dizziness prescribed by the out-of-hours service. What is the single most likely explanation for his deteriorating Parkinson's symptoms?

Q135

During a practice audit of patients aged over 75 on 10 or more medications, you identify that 23% are taking a proton pump inhibitor (PPI) without documented indication. Which single action represents the most appropriate quality improvement intervention?

Q136

A 70-year-old woman attends for a medication review. She has hypertension, type 2 diabetes, hypothyroidism, and recurrent urinary tract infections. She takes amlodipine, metformin, gliclazide, levothyroxine, and has been on prophylactic trimethoprim 100mg daily for 6 months following three UTIs in 4 months. Her recent HbA1c is 48 mmol/mol, BP 132/78 mmHg, eGFR 52 ml/min/1.73m². She has had no further UTIs. What is the single most appropriate next step in her medication management?

Q137

An 81-year-old man with heart failure (LVEF 35%), atrial fibrillation, type 2 diabetes, and osteoarthritis attends for review. His medications include bisoprolol, ramipril, spironolactone, furosemide, apixaban, metformin, and co-codamol. He reports increasing constipation and reduced mobility. His most recent blood results show: Na+ 133 mmol/L, K+ 5.4 mmol/L, eGFR 34 ml/min/1.73m². Which single combination of factors most strongly suggests the need for urgent medication review?

Q138

You are conducting annual medication reviews in your practice. According to the NICE guideline on multimorbidity, which single criterion best defines a structured medication review approach?

Q139

A 74-year-old woman with type 2 diabetes, hypertension, osteoarthritis, and depression is taking metformin, ramipril, amlodipine, paracetamol, ibuprofen, sertraline, and omeprazole. She reports a recent fall at home. On examination, her BP is 108/62 mmHg sitting and 88/54 mmHg standing. Her eGFR is 38 ml/min/1.73m². Which single medication is the most appropriate to discontinue first?

Q140

You are analyzing prescribing quality indicators for your practice and identify a 73-year-old man with heart failure (ejection fraction 35%), post-myocardial infarction (18 months ago), hypertension, and type 2 diabetes who is currently taking aspirin, atorvastatin, ramipril 10mg daily, bisoprolol 10mg daily, furosemide 40mg daily, metformin, and empagliflozin. His recent blood pressure is 128/76 mmHg, heart rate 68 bpm, eGFR 48 ml/min/1.73m², potassium 4.3 mmol/L. According to current NICE guidance on optimizing heart failure with reduced ejection fraction treatment, which medication addition would provide the GREATEST mortality benefit?

Chronic Disease Management UK Medical PG Practice Questions and MCQs

Question 131: According to the STOPP/START criteria for potentially inappropriate prescribing in older adults, which single statement most accurately describes the principle behind these criteria?

A. STOPP identifies medications to stop in all circumstances, START identifies essential medications that must be prescribed
B. STOPP identifies potentially inappropriate medications, START identifies potentially beneficial medications that may be omitted (Correct Answer)
C. STOPP focuses on drug-drug interactions, START focuses on drug-disease interactions
D. STOPP applies only to patients over 80 years, START applies to patients over 65 years
E. STOPP addresses polypharmacy by limiting prescriptions to maximum 8 medications in older adults

Explanation: ***STOPP identifies potentially inappropriate medications, START identifies potentially beneficial medications that may be omitted*** - **STOPP** (Screening Tool of Older Persons' Prescriptions) aims to reduce **adverse drug reactions** by identifying medications where the risks may outweigh clinical benefits in older adults. - **START** (Screening Tool to Alert to Right Treatment) addresses **under-prescribing** by highlighting evidence-based medications that should be considered for specific clinical conditions that are currently untreated. *STOPP identifies medications to stop in all circumstances, START identifies essential medications that must be prescribed* - These criteria are **advisory tools** and do not mandate absolute clinical actions; they require **clinical judgment** based on individual patient goals and clinical context. - The phrase "in all circumstances" is inaccurate as medication appropriateness is highly **patient-specific** and context-dependent, not an absolute rule. *STOPP focuses on drug-drug interactions, START focuses on drug-disease interactions* - Both STOPP and START address a broad range of issues, including **drug-disease interactions**, **duplicate therapy**, and medications without a clear **indication**, not just drug-drug interactions. - While they include some **drug-drug interactions**, this is not the exclusive or primary focus of either component of the criteria. *STOPP applies only to patients over 80 years, START applies to patients over 65 years* - Both STOPP and START criteria are designed for use in **older adults**, generally defined as those aged **65 years and older**, without a specific differential age cut-off for each tool. - The application is based on the **vulnerability** and **polypharmacy risk** often associated with advanced age, not arbitrary age limits of 80 or 65 years for distinct tools. *STOPP addresses polypharmacy by limiting prescriptions to maximum 8 medications in older adults* - The criteria focus on the **appropriateness** and **clinical necessity** of individual medications rather than enforcing an an arbitrary numerical limit on the total number of prescriptions. - While they indirectly help manage **polypharmacy** by identifying unnecessary or missing medications, they do not define a specific cut-off like "maximum 8 medications."

Question 132: A 73-year-old man with COPD, ischaemic heart disease, heart failure with preserved ejection fraction (HFpEF), and type 2 diabetes attends for medication review. He takes aspirin, atorvastatin, bisoprolol, furosemide, metformin, and uses tiotropium and salbutamol inhalers. He reports increasing breathlessness. Examination reveals bibasal fine crackles, mild peripheral oedema, and peak expiratory flow rate 65% of predicted (unchanged from previous). Which single medication change is most likely to improve his symptoms?

A. Add spironolactone for additional diuretic effect in heart failure
B. Increase furosemide dose to manage fluid overload more effectively (Correct Answer)
C. Stop bisoprolol as it may worsen COPD and contribute to breathlessness
D. Add a long-acting beta-agonist (LABA) inhaler for better COPD control
E. Add ramipril as ACE inhibitors benefit both heart failure and diabetes

Explanation: ***Increase furosemide dose to manage fluid overload more effectively*** - The presence of **bibasal fine crackles**, **peripheral oedema**, and increasing breathlessness, alongside an *unchanged* **peak flow rate**, strongly indicates **fluid overload** due to **heart failure decompensation** (HFpEF). - **Loop diuretics** like **furosemide** are the most effective intervention for acute symptom relief in **HFpEF** by promoting **diuresis** and reducing congestion, directly addressing the patient's immediate problem. *Add spironolactone for additional diuretic effect in heart failure* - While **mineralocorticoid receptor antagonists (MRAs)** like **spironolactone** are beneficial in HFpEF for reducing hospitalizations, their role is not for rapid **symptomatic relief** of acute volume overload. - Optimizing the dose of the existing **loop diuretic** (furosemide) is the primary and most direct approach to achieve timely **decongestion** when fluid overload is evident. *Stop bisoprolol as it may worsen COPD and contribute to breathlessness* - **Cardioselective beta-blockers** such as **bisoprolol** are generally safe in patients with stable **COPD** and are crucial for improving outcomes in patients with **ischaemic heart disease** and heart failure. - Abruptly stopping **bisoprolol** could worsen the patient's underlying **ischaemic heart disease** or heart failure, potentially leading to **tachycardia** or increased myocardial oxygen demand. *Add a long-acting beta-agonist (LABA) inhaler for better COPD control* - The patient's **peak expiratory flow rate (PEFR)** is *unchanged* from previous, suggesting that his **COPD** is stable and not the primary cause of his acute increase in breathlessness. - A **LABA** is indicated for persistent respiratory symptoms in COPD, but it would not address the **bibasal crackles** and **peripheral oedema**, which point to a cardiac cause. *Add ramipril as ACE inhibitors benefit both heart failure and diabetes* - **ACE inhibitors** are beneficial in many cardiovascular conditions and diabetes, but their mortality benefit in **HFpEF** is less established compared to **HFrEF**. - While potentially useful long-term, initiating an **ACE inhibitor** will not provide the rapid **diuresis** and symptomatic relief from **fluid overload** that the patient currently needs.

Question 133: You are reviewing prescribing patterns in patients with multimorbidity in your practice. A 79-year-old woman with heart failure, atrial fibrillation, chronic kidney disease stage 3b, and previous gastrointestinal bleeding is taking bisoprolol, furosemide, apixaban 2.5mg twice daily, lansoprazole, and ferrous sulfate. Her weight is 54kg, creatinine 145 μmol/L, and age is 79 years. According to the apixaban dose reduction criteria, how many factors does she have that would justify the reduced dose she is receiving?

A. None - she should be on the standard 5mg twice daily dose
B. One factor only
C. Two factors meeting the criteria for dose reduction (Correct Answer)
D. Three factors all meeting dose reduction criteria
E. Dose reduction is appropriate due to previous GI bleeding regardless of other factors

Explanation: ***Two factors meeting the criteria for dose reduction*** - Apixaban requires a dose reduction to 2.5mg twice daily if at least **two of three** criteria are met: **age ≥80 years**, **weight ≤60kg**, or **serum creatinine ≥133 μmol/L**. - This patient meets **two factors**: her weight of **54kg** is below 60kg, and her serum creatinine of **145 μmol/L** is above 133 μmol/L. Her age of 79 years does not meet the 80 years threshold.*None - she should be on the standard 5mg twice daily dose* - This is incorrect because the patient already satisfies the **mandatory threshold** (two criteria) for a lower dose to prevent toxicity. - Standard dosing (5mg) in patients meeting these criteria significantly increases the risk of **major bleeding** events.*One factor only* - Although the patient's age (79) is close to the threshold, only **weight** and **creatinine** qualify as positive criteria in this scenario. - Identifying only one factor would mistakenly suggest she should be on the higher 5mg dose, which is clinically inappropriate here.*Three factors all meeting dose reduction criteria* - The patient is **79 years old**, which does not meet the age criterion of **≥80 years** required for the third factor. - While she has multimorbidity, the specific pharmacokinetic rules for **Apixaban** are strictly defined by those three specific clinical parameters.*Dose reduction is appropriate due to previous GI bleeding regardless of other factors* - A history of **gastrointestinal bleeding** is a clinical concern but is not a formal criterion for the automatic dose reduction of Apixaban in **atrial fibrillation**. - Clinical guidelines for AFib require dose adjustment based on the **ABC criteria** (Age, Body weight, Creatinine) rather than just bleeding history alone.

Question 134: A 76-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and anxiety presents with worsening tremor and rigidity. His medications include co-careldopa, atorvastatin, metformin, tamsulosin, and he recently started prochlorperazine for dizziness prescribed by the out-of-hours service. What is the single most likely explanation for his deteriorating Parkinson's symptoms?

A. Natural progression of Parkinson's disease requiring increased co-careldopa dose
B. Drug interaction between tamsulosin and co-careldopa reducing levodopa efficacy
C. Prochlorperazine-induced dopamine antagonism worsening Parkinsonian symptoms (Correct Answer)
D. Atorvastatin-related myopathy mimicking worsening Parkinson's disease
E. Metformin-induced vitamin B12 deficiency affecting neurological function

Explanation: ***Prochlorperazine-induced dopamine antagonism worsening Parkinsonian symptoms***- **Prochlorperazine** is a first-generation **dopamine D2 receptor antagonist** that can cross the blood-brain barrier and directly counteract the effects of **levodopa**.- Its use is contraindicated in patients with **Parkinson’s disease** as it significantly exacerbates motor symptoms like **tremor** and **rigidity**; safer alternatives include **cyclizine** or **domperidone**.*Natural progression of Parkinson's disease requiring increased co-careldopa dose*- While Parkinson's is a **progressive neurodegenerative** condition, the acute deterioration following a new medication suggests an **iatrogenic** cause rather than natural decline.- **Temporal association** with the initiation of the out-of-hours prescription makes pharmaceutical interference the primary suspect.*Drug interaction between tamsulosin and co-careldopa reducing levodopa efficacy*- **Tamsulosin** is an alpha-1 blocker used for BPH; it does not interfere with the **mechanism of action** or absorption of **levodopa**.- Potential side effects of combining these include **orthostatic hypotension**, but not a direct increase in **extrapyramidal symptoms**.*Atorvastatin-related myopathy mimicking worsening Parkinson's disease*- **Statin-induced myopathy** typically presents with symmetrical **proximal muscle pain** and weakness, rather than an increase in **resting tremor** or **lead-pipe rigidity**.- It is often associated with elevated **creatine kinase (CK)** levels and does not explain the worsening of specific neurological motor signs.*Metformin-induced vitamin B12 deficiency affecting neurological function*- Long-term **metformin** use can cause **vitamin B12 deficiency**, which usually presents as **subacute combined degeneration** of the cord or **peripheral neuropathy**.- This deficiency leads to sensory loss and **atxia** rather than the acute worsening of core **Parkinsonian motor features**.

Question 135: During a practice audit of patients aged over 75 on 10 or more medications, you identify that 23% are taking a proton pump inhibitor (PPI) without documented indication. Which single action represents the most appropriate quality improvement intervention?

A. Send letters to all affected patients asking them to stop their PPI immediately
B. Generate a list for clinical review to assess for appropriate deprescribing with individual patient consultations (Correct Answer)
C. Change practice policy to automatically stop PPIs after 8 weeks unless consultant-initiated
D. Add a PPI monitoring template to be completed annually for all patients
E. Send an email to all prescribers reminding them of PPI prescribing guidelines

Explanation: ***Generate a list for clinical review to assess for appropriate deprescribing with individual patient consultations***- **Individualized patient consultation** is essential to ensure safe **deprescribing**, as it allows the clinician to identify undocumented indications and discuss potential **rebound acid hypersecretion**.- This approach promotes **shared decision-making** and addresses risks associated with long-term PPI use such as **osteoporosis**, **hypomagnesaemia**, and **C. difficile infection**.*Send letters to all affected patients asking them to stop their PPI immediately*- Stopping medications abruptly via letter is unsafe as it lacks the necessary **clinical oversight** to prevent complications or symptom relapse.- It fails to differentiate between patients who may actually have a **valid clinical need** for the medication that was simply not documented correctly.*Change practice policy to automatically stop PPIs after 8 weeks unless consultant-initiated*- Rigid automatic stop policies do not account for **patient-specific clinical requirements** and can lead to inadequate treatment for chronic conditions like **Barrett's esophagus**.- Primary care clinicians have the authority to initiate and continue PPIs without consultant input if there is a **valid clinical indication**.*Add a PPI monitoring template to be completed annually for all patients*- While a template might improve documentation, it does not directly address the **quality improvement** goal of reducing **inappropriate polypharmacy** in this specific cohort.- Monitoring alone does not actively facilitate the **deprescribing process** for those who no longer require the medication.*Send an email to all prescribers reminding them of PPI prescribing guidelines*- Education-based interventions (passive dissemination) are generally less effective than **active clinical review** in changing practice outcomes or addressing existing errors.- An email reminder does not systematically identify or manage the **23% of patients** already identified as being on potentially inappropriate therapy.

Question 136: A 70-year-old woman attends for a medication review. She has hypertension, type 2 diabetes, hypothyroidism, and recurrent urinary tract infections. She takes amlodipine, metformin, gliclazide, levothyroxine, and has been on prophylactic trimethoprim 100mg daily for 6 months following three UTIs in 4 months. Her recent HbA1c is 48 mmol/mol, BP 132/78 mmHg, eGFR 52 ml/min/1.73m². She has had no further UTIs. What is the single most appropriate next step in her medication management?

A. Continue trimethoprim prophylaxis for a total of 12 months then review
B. Stop trimethoprim and provide advice on non-antibiotic measures for UTI prevention (Correct Answer)
C. Switch trimethoprim to nitrofurantoin for long-term prophylaxis given better safety profile
D. Stop gliclazide as HbA1c is well controlled and reduce hypoglycaemia risk
E. Reduce amlodipine dose as blood pressure target is achieved

Explanation: ***Stop trimethoprim and provide advice on non-antibiotic measures for UTI prevention***- Guidelines recommend that **antibiotic prophylaxis** for recurrent UTIs should be reviewed and usually **discontinued after 6 months** if the patient remains infection-free.- Stopping the medication reduces the risk of **antimicrobial resistance**, side effects, and promotes **non-antibiotic measures** like hydration and hygiene for long-term prevention.*Continue trimethoprim prophylaxis for a total of 12 months then review*- Prophylaxis is typically intended for a **3 to 6-month period**; extending it to 12 months without further infections unnecessarily increases the risk of **adverse effects**.- Continuing treatment in a patient who has been stable for 6 months goes against the principles of **antibiotic stewardship**.*Switch trimethoprim to nitrofurantoin for long-term prophylaxis given better safety profile*- Switching to another antibiotic is not indicated when the current goal should be **discontinuation** due to successful prevention and the absence of further UTIs.- **Nitrofurantoin** carries risks of pulmonary and hepatic toxicity with long-term use, and its efficacy is reduced in patients with an **eGFR below 60 ml/min**, like this patient's eGFR of 52.*Stop gliclazide as HbA1c is well controlled and reduce hypoglycaemia risk*- An **HbA1c of 48 mmol/mol** reflects good control, but completely stopping a **sulfonylurea** like gliclazide without evidence of hypoglycemic episodes could lead to a loss of glycemic control.- The primary concern in this medication review is the **long-term antibiotic use**, which has reached its recommended duration limit, rather than adjusting well-controlled diabetes medication.*Reduce amlodipine dose as blood pressure target is achieved*- The blood pressure of **132/78 mmHg** is within the target range for a patient with diabetes and hypertension, suggesting the current dose of **amlodipine** is appropriate and effective.- Reducing the dose purely because the target is met may lead to **rebound hypertension** and an increased cardiovascular risk, while the current regimen is clearly working.

Question 137: An 81-year-old man with heart failure (LVEF 35%), atrial fibrillation, type 2 diabetes, and osteoarthritis attends for review. His medications include bisoprolol, ramipril, spironolactone, furosemide, apixaban, metformin, and co-codamol. He reports increasing constipation and reduced mobility. His most recent blood results show: Na+ 133 mmol/L, K+ 5.4 mmol/L, eGFR 34 ml/min/1.73m². Which single combination of factors most strongly suggests the need for urgent medication review?

A. Hyponatraemia and reduced eGFR indicating over-diuresis requiring furosemide dose reduction
B. High-normal potassium and reduced eGFR suggesting risk of hyperkalaemia from combined ACE inhibitor and spironolactone (Correct Answer)
C. Constipation and reduced mobility suggesting opioid-related adverse effects requiring laxatives
D. Multiple cardiac medications and diabetes suggesting polypharmacy requiring simplification
E. Atrial fibrillation and reduced eGFR suggesting apixaban dose adjustment needed

Explanation: ***High-normal potassium and reduced eGFR suggesting risk of hyperkalaemia from combined ACE inhibitor and spironolactone*** - The concurrent use of **ramipril** (ACE inhibitor) and **spironolactone** (mineralocorticoid receptor antagonist) in a patient with significantly decreased **eGFR (34 ml/min/1.73m²)** creates a high risk for life-threatening **hyperkalaemia**. - A potassium level of **5.4 mmol/L** is at the upper limit of normal; given the renal impairment, these medications require urgent review to prevent serious **cardiac arrhythmias**. *Hyponatraemia and reduced eGFR indicating over-diuresis requiring furosemide dose reduction* - While **furosemide** and **ramipril** can contribute to **hyponatraemia** (133 mmol/L), this mild electrolyte imbalance is less acutely dangerous than the potential for rapidly rising potassium in a renally impaired patient. - Reduced **eGFR** in heart failure often necessitates careful balancing of diuresis with perfusion, making this a management consideration rather than the most urgent safety risk. *Constipation and reduced mobility suggesting opioid-related adverse effects requiring laxatives* - **Co-codamol** frequently causes **constipation**, which can reduce the mobility of an elderly patient and significantly impact their quality of life. - While important for patient comfort and overall well-being, these symptoms do not pose an immediate **biochemical or life-threatening risk** compared to the profound dangers of hyperkalaemia. *Multiple cardiac medications and diabetes suggesting polypharmacy requiring simplification* - The patient is receiving **Guideline-Directed Medical Therapy (GDMT)** for heart failure with reduced ejection fraction (LVEF 35%), which inherently involves **polypharmacy**. - While polypharmacy merits regular review, simplifying for the sake of reducing pill count is secondary to managing the **acute safety risks** associated with specific drug-drug and drug-disease interactions. *Atrial fibrillation and reduced eGFR suggesting apixaban dose adjustment needed* - **Apixaban** dosing for atrial fibrillation generally requires adjustment if at least two of the following criteria are met: age ≥80 years, weight ≤60 kg, or **creatinine ≥133 µmol/L**. - With an **eGFR of 34 ml/min/1.73m²**, a dose adjustment might be necessary, but this logistical dose check is less urgent than addressing the patient's immediate **potassium levels and renal status** to prevent life-threatening complications.

Question 138: You are conducting annual medication reviews in your practice. According to the NICE guideline on multimorbidity, which single criterion best defines a structured medication review approach?

A. Reviewing all medications prescribed in the past 12 months and discontinuing those without clear indication
B. Prioritizing medications based on drug costs and stopping the most expensive unnecessary treatments
C. Assessing individual medications against patient's current conditions, considering risks, benefits, and patient preferences (Correct Answer)
D. Using only the Beers Criteria to identify potentially inappropriate medications in all adult patients
E. Conducting annual blood tests to monitor for drug interactions and adverse effects

Explanation: ***Assessing individual medications against patient's current conditions, considering risks, benefits, and patient preferences*** - NICE guidelines for **multimorbidity (NG56)** define a structured medication review as a comprehensive, **patient-centered** assessment aimed at optimizing the balance of **clinical benefit and harm**. - It emphasizes **shared decision-making**, ensuring treatment aligns with the patient's personal **values, preferences, and treatment goals** in the context of multiple chronic conditions. *Reviewing all medications prescribed in the past 12 months and discontinuing those without clear indication* - While identifying **polypharmacy** and omitting drugs without indication is part of the process, it lacks the broader assessment of **patient-focused goals** required by NICE. - This approach is purely clinical and does not necessarily incorporate the **patient's voice** or the complex interaction of multimorbidities. *Prioritizing medications based on drug costs and stopping the most expensive unnecessary treatments* - The primary goal of a structured clinical review is **patient safety** and **clinical effectiveness**, not cost-saving or budgetary prioritisation. - Decisions should be based on the **risk-benefit ratio** for the individual patient rather than the unit price of the medication. *Using only the Beers Criteria to identify potentially inappropriate medications in all adult patients* - The **Beers Criteria** is specifically developed for **older adults** (typically >65) and lacks evidence-based applicability for the general adult population with multimorbidity. - A structured review should use various tools (like **STOPP/START criteria**) but must ultimately rely on personalized clinical judgment rather than a single checklist. *Conducting annual blood tests to monitor for drug interactions and adverse effects* - Biological monitoring is a component of **medication safety** and surveillance but does not constitute the holistic **structured review** process described by NICE. - Monitoring is a reactive or maintenance step, whereas a structured review is an active **re-evaluation** of the entire therapeutic strategy.

Question 139: A 74-year-old woman with type 2 diabetes, hypertension, osteoarthritis, and depression is taking metformin, ramipril, amlodipine, paracetamol, ibuprofen, sertraline, and omeprazole. She reports a recent fall at home. On examination, her BP is 108/62 mmHg sitting and 88/54 mmHg standing. Her eGFR is 38 ml/min/1.73m². Which single medication is the most appropriate to discontinue first?

A. Amlodipine
B. Ibuprofen (Correct Answer)
C. Omeprazole
D. Ramipril
E. Sertraline

Explanation: ***Ibuprofen*** - **NSAIDs** are contraindicated in patients with an **eGFR < 30** and should be used with extreme caution or stopped in those with an eGFR of **38 ml/min/1.73m² (CKD stage 3b)** due to the risk of acute kidney injury. - Stopping ibuprofen reduces the risk of **renal deterioration** and gastrointestinal complications, while paracetamol remains a safer alternative for her **osteoarthritis**. *Amlodipine* - While this **calcium channel blocker** may contribute to hypotension, it is less likely than other agents to cause significant **postural hypotension** leading to falls. - Management of blood pressure is secondary to preventing **nephrotoxicity** from NSAIDs in the setting of established renal impairment. *Omeprazole* - **Proton pump inhibitors** are not typically associated with **postural hypotension** or an increased risk of falls in the acute setting. - While long-term use has risks like **fractures** or C. difficile, it is not the most urgent priority compared to managing her **renal health**. *Ramipril* - Although this **ACE inhibitor** can cause hypotension and may need dose adjustment, it provides essential **renoprotection** and cardiovascular benefits for a diabetic patient. - Discontinuing this before the **nephrotoxic NSAID** would be counterproductive for managing her **diabetic kidney disease**. *Sertraline* - **SSRIs** are associated with an increased fall risk in the elderly due to **hyponatremia** or sedation, but they do not cause the patient's primary renal issue. - Sudden discontinuation of sertraline can lead to **discontinuation syndrome**, making it a less suitable choice for immediate withdrawal over an NSAID.

Question 140: You are analyzing prescribing quality indicators for your practice and identify a 73-year-old man with heart failure (ejection fraction 35%), post-myocardial infarction (18 months ago), hypertension, and type 2 diabetes who is currently taking aspirin, atorvastatin, ramipril 10mg daily, bisoprolol 10mg daily, furosemide 40mg daily, metformin, and empagliflozin. His recent blood pressure is 128/76 mmHg, heart rate 68 bpm, eGFR 48 ml/min/1.73m², potassium 4.3 mmol/L. According to current NICE guidance on optimizing heart failure with reduced ejection fraction treatment, which medication addition would provide the GREATEST mortality benefit?

A. Add spironolactone 25mg daily for additional mineralocorticoid receptor antagonism (Correct Answer)
B. Add ivabradine to reduce heart rate further below 60 bpm
C. Add hydralazine and isosorbide dinitrate for additional vasodilation
D. Add digoxin to improve symptoms and reduce hospitalizations
E. No additional medication needed as patient is on optimal medical therapy

Explanation: ***Add spironolactone 25mg daily for additional mineralocorticoid receptor antagonism*** - This patient is missing a **Mineralocorticoid Receptor Antagonist (MRA)**, one of the four foundational drug classes for **Heart Failure with reduced Ejection Fraction (HFrEF)**, which offers a significant **mortality benefit**. - His current **eGFR** (48 ml/min/1.73m²) and **potassium** (4.3 mmol/L) are within the safe parameters for initiating spironolactone according to **NICE guidelines**. *Add ivabradine to reduce heart rate further below 60 bpm* - **Ivabradine** is indicated for patients in **sinus rhythm** with a heart rate of **≥ 75 bpm** (NICE) or **> 70 bpm** (ESC) despite optimal beta-blocker therapy. - The patient's heart rate of **68 bpm** does not meet the established criteria for initiating ivabradine, making it an unsuitable next step. *Add hydralazine and isosorbide dinitrate for additional vasodilation* - This combination is typically reserved for patients of **Black African or Caribbean origin** or those who are **intolerant to ACE inhibitors/ARBs/ARNIs**. - While it can improve outcomes, it does not provide the *greatest mortality benefit* as the next addition for a general HFrEF patient who is already tolerating ACEi, beta-blocker, and SGLT2i, compared to an MRA. *Add digoxin to improve symptoms and reduce hospitalizations* - **Digoxin** can improve symptoms and reduce hospitalizations in patients with severe HFrEF, particularly those with atrial fibrillation, but it has **no proven mortality benefit**. - The question specifically asks for the medication providing the **greatest mortality benefit**, which digoxin does not offer. *No additional medication needed as patient is on optimal medical therapy* - This statement is incorrect because the patient is currently on three of the **four pillar** medications for HFrEF (ACE inhibitor, beta-blocker, and SGLT2 inhibitor). - **Optimal Medical Therapy (OMT)** for HFrEF includes the addition of an **MRA** (like spironolactone) to maximize survival benefit.

Practice by Chapter

Medication reviews

Practice Questions

Multimorbidity

Practice Questions

Polypharmacy

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free